A combination of the plant-derived compound ibogaine with magnesium, given alongside complementary treatments, led to large improvements in functioning, PTSD, depression, and anxiety in 30 male Special Operations Forces veterans with mild traumatic brain injury. Functioning improved significantly both immediately after treatment and one month later, with very large effects on PTSD, depression, and anxiety at one month. No serious adverse events occurred. The authors call for controlled trials to confirm these initial open-label findings.
Among 30 male Veterans with traumatic brain injury from repeated blast/combat exposures, those who reported more intense mystical experiences during magnesium-ibogaine therapy showed larger reductions in PTSD severity both immediately and one month after treatment. Greater mystical experience intensity was also linked to larger reductions in peak alpha frequency one month later. The findings suggest that mystical experiences may contribute to improvements in PTSD following magnesium-ibogaine and may relate to persisting decreases in peak alpha frequency.
In a small study of 22 military veterans with traumatic brain injury, a single treatment with magnesium-ibogaine was associated with changes in brain structure one month later. Brain scans showed an average reduction in predicted brain age of 1.3 years, increased thickness in 11 cortical regions, and volume expansion in 8 subcortical regions. While the authors note that the imaging technique can also reflect nonstructural changes, the overall pattern of results is consistent with neuroplastic change.
A single dose of magnesium-ibogaine produced large and lasting reductions in disability, posttraumatic stress disorder, depression, and anxiety symptoms over 12 months in male U.S. Special Operations Veterans with a history of traumatic brain injury. Of 30 treated participants, 25 completed the full year of follow-up. Effect sizes at 12 months were very large (Cohen's d ≥ 2.18). The estimated probability of sustained remission at one year was 84% for PTSD, 66% for depression, and 61% for anxiety. These results suggest ibogaine may offer durable clinical benefits for TBI-related psychiatric and functional problems, though randomized controlled trials are needed to confirm the findings.